Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand (PD-L1) interaction have shifted the treatment landscape of advanced cancers and significantly improved the overall survival (OS) (9–12). Here, PDCD1 is linked to cancer.